Evidence map›Paper›PMID 41250542›Full record

ArticleZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics2025

[Ultra-early administration of eculizumab in a child with atypical hemolytic uremic syndrome: a case report].

Dan-Dan Guo, Yi-Xin Xiao, Wei-Rui Wang, Xiao-Lu Deng, Ye-Hong Huang

Abstract readCase ReportsEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dan-Dan GuoDepartment of Pediatrics, Xiangya Hospital of Central South University, Changsha 410008, China.
Yi-Xin XiaoDepartment of Pediatrics, Xiangya Hospital of Central South University, Changsha 410008, China.
Wei-Rui WangDepartment of Pediatrics, Xiangya Hospital of Central South University, Changsha 410008, China.
Xiao-Lu DengDepartment of Pediatrics, Xiangya Hospital of Central South University, Changsha 410008, China.
Ye-Hong HuangDepartment of Pediatrics, Xiangya Hospital of Central South University, Changsha 410008, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 10-year-old girl was admitted with a 38-hour history of widespread subcutaneous petechiae and hematuria and a 6-hour history of jaundice and oliguria. Physical examination revealed widespread subcutaneous petechiae and jaundice of the skin and sclera. Laboratory tests showed anemia, thrombocytopenia, acute kidney injury, and markedly elevated lactate dehydrogenase. Thrombotic microangiopathy was initially diagnosed, with a high suspicion of atypical hemolytic uremic syndrome (aHUS). Eculizumab was initiated within 9 hours of admission (within 48 hours of onset). After the first infusion, hemolysis rapidly ceased, and the platelet count and renal function gradually returned to normal. Whole-exome sequencing identified homozygous deletions of

Indexed as

Antibodies, Monoclonal, HumanizedAtypical Hemolytic Uremic SyndromeChildComplement C3b Inactivator ProteinsFemaleHumansAntibodies, Monoclonal, HumanizedCFHR1 protein, humanComplement C3b Inactivator ProteinseculizumabAtypical hemolytic uremic syndromeChildEculizumabUltra-early therapy

Identifiers

PMID41250542
PMCPMC12688181

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.